INSM Stock Price Today (October 2026) — Insmed Incorporated Analysis & Key Metrics 2026-10-20
Insmed Incorporated (INSM) is trading at $95.67, up 0.40% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $197.00 (105.9% upside).
- Volatility is moderate (35.72% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (296.10% YoY) alongside competitive pressures in the Biotechnology space.
INSM Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Insmed Incorporated - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $20.47B
P/E Ratio
Forward P/E: 151.85
Revenue Growth
Year over Year
Analyst Target
+105.9% upside potential
Key Investor Questions About INSM
What investors need to know before buying
Based on current market data, INSM presents a oversold technical setup with looking solid fundamentals.
- Technicals say: Oversold (RSI 25.77)
- Fundamentals say: Looking solid (debt and growth supportive)
INSM's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for INSM investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $739.72M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, INSM stock traded between $90.39 and $212.75 and currently trades near the low end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 35.72% annualized volatility and β=0.62, the stock exhibits low sensitivity to market moves—making INSM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Insmed Appoints Two New Directors to Its Board
Insmed Launches Brinsupri Tablet in Japan for Non-Cystic Fibrosis Bronchiectasis
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
Insmed Shares Fall After Wolfe Research Downgrade
Latest TickZen Insights
All insights →No TickZen article on INSM yet. Our newest analysis:
Explore More Analysis for INSM
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Insmed Incorporated
Insmed Incorporated (INSM) is currently trading at $95.67. The RSI (14-day) is at 25.8, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $197.00 implies 105.9% upside from current levels. Volatility is moderate at 35.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Insmed Incorporated (INSM): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is 151.85. Price-to-Book is 36.11. Price-to-Sales is 24.05. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering INSM, the consensus price target is $197.00. This represents a 105.9% upside from the current price of $95.67. The range spans from a low target of $165.00 to a high target of $243.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Insmed Incorporated (INSM) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Insmed Incorporated (INSM) investors include: 1. Moderate volatility (35.7% annualized)—price swings are notable. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Insmed Incorporated's (INSM) current debt and financial health profile: Total debt stands at $739.72M. The debt-to-equity ratio is 0.98x, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 3.72, indicating strong short-term liquidity. The quick ratio is 3.14. The company holds $1.16B in cash and equivalents. Free cash flow is negative at -$571.82M, which could limit the company's ability to manage debt obligations.